

Psychedelic Assisted Psychotherapy for Treatment Resistant Disorders Mechanisms Evidence and Future Directions

Liang Zhou*

Department of health science, University of Pennsylvania, USA

*Corresponding author:

Liang Zhou

✉ Zho_12lia@hotmail.com

Department of health science, University of Pennsylvania, USA

Citation: Zhou L (2024) Psychedelic Assisted Psychotherapy for Treatment Resistant Disorders Mechanisms Evidence and Future Directions. Health Sci J. Vol. 18 No. 11: 1203.

Abstract

Psychedelic-assisted psychotherapy (PAP) is gaining attention as a novel and promising treatment for a range of mental health disorders, particularly those resistant to conventional therapies. Disorders such as depression, anxiety, post-traumatic stress disorder (PTSD), and substance use disorders have shown limited response to traditional treatments, prompting the exploration of psychedelics like psilocybin, MDMA, and LSD as adjuncts to psychotherapy. This review examines the current state of research into psychedelic-assisted psychotherapy, its mechanisms of action, the clinical evidence supporting its efficacy for treatment-resistant disorders, and the challenges and future directions of this therapeutic approach. By facilitating profound therapeutic experiences, psychedelics may help patients access deep emotional insights, enhance neuroplasticity, and reframe trauma or ingrained mental patterns, offering new hope for those with chronic mental health conditions.

Keywords: Psychedelic-Assisted Psychotherapy; Psilocybin

Received: 2-Nov-2024, Manuscript No. Iphsj-24-15443; **Editor assigned:** 5-Nov-2024, Preqc No. PQ-15443; **Reviewed:** 20-Nov-2024, QC No.Q-15443; **Revised:** 26-Nov-2024, Manuscript No. Iphsj-24-15443 (R); **Published:** 30-Nov-2024; DOI: 10.36648/1791-809X.18.11.1203

Introduction

Mental health disorders such as depression, anxiety, post-traumatic stress disorder (PTSD), and substance use disorders continue to burden millions of individuals worldwide. Despite significant advances in psychotherapy and pharmacotherapy, a substantial portion of patients remain resistant to conventional treatments. As a result, researchers have begun to explore alternative therapeutic modalities, including psychedelic-assisted psychotherapy (PAP), as a promising option for treatment-resistant disorders [1]. Psychedelics, including psilocybin (the active compound in "magic mushrooms"), MDMA (commonly known as ecstasy), and LSD, have demonstrated therapeutic potential in combination with psychotherapy. The idea of using psychedelics to enhance psychotherapy is not new such treatments were explored extensively in the 1950s and 1960s before being outlawed. However, with the resurgence of interest in psychedelics in recent years, rigorous clinical studies have begun to evaluate their efficacy in treating a variety of mental health conditions. This review discusses the mechanisms by which psychedelics assist psychotherapy, evaluates the current evidence supporting their effectiveness in treating mental health disorders, and examines the future potential and challenges of integrating these substances into mainstream mental health care [2].

Mechanisms of Action: How Psychedelics Facilitate Psychotherapy

Psychedelics are thought to facilitate psychotherapy through several interrelated mechanisms that enhance the therapeutic process. These mechanisms include:

Neuroplasticity and Brain Network Modulation

Psychedelics have been shown to enhance neuroplasticity, the brain's ability to reorganize and form new neural connections. By increasing the flexibility of neural circuits, psychedelics may help individuals "break free" from rigid, maladaptive thought patterns associated with mental health disorders. For example, in individuals with depression, brain networks involved in negative thought cycles may become overactive and entrenched. Psychedelics, through their action on serotonin receptors (especially 5-HT_{2A} receptors), are thought to increase connectivity between different brain regions, enabling patients to reframe their thoughts and emotions in novel ways [3]. A study published in Cell Reports demonstrated that psilocybin and other psychedelics promote synaptogenesis and dendritic growth, potentially facilitating the rewiring of neural circuits. This neuroplasticity is thought to be essential for the therapeutic breakthroughs often experienced in psychedelic-assisted psychotherapy.

Altered States of Consciousness and Emotional Processing

Psychedelics induce altered states of consciousness that may help individuals access deeply buried emotions, memories, or traumatic experiences. These states, often described as "mystical" or "transcendent" experiences, allow patients to confront difficult feelings or events from a detached perspective, leading to emotional catharsis. In the context of PTSD, for example, psychedelics may allow patients to revisit traumatic memories without becoming overwhelmed by them, providing an opportunity for cognitive reframing and emotional processing. The increased emotional sensitivity during a psychedelic experience can also enhance therapeutic breakthroughs, allowing patients to access a higher level of introspection and self-awareness. This emotional release is thought to facilitate the integration of these experiences into the psychotherapeutic process, leading to long-term healing.

Increased Connectivity Between Brain Regions

Neuroimaging studies have demonstrated that psychedelics induce changes in brain activity, particularly in the default mode network (DMN), which is often overactive in individuals with conditions like depression and anxiety [4]. The DMN is responsible for self-referential thinking and rumination, and its overactivity is associated with maladaptive thought patterns. Psychedelics decrease the dominance of the DMN, fostering a more fluid, interconnected brain state. As a result, patients may experience a reduction in rumination and a shift towards more adaptive ways of thinking. This shift is accompanied by increased communication between the DMN and other brain networks involved in perception, emotion, and executive function [5]. Such changes are believed to be instrumental in the therapeutic effects of psychedelic-assisted psychotherapy, helping patients gain new insights and resolve deep-seated psychological conflicts.

Clinical Evidence for Psychedelic-Assisted Psychotherapy

Psilocybin for Depression

Psilocybin, a naturally occurring psychedelic, has been studied extensively for its effects on depression. In a landmark study published in *JAMA Psychiatry*, patients with major depressive disorder (MDD) who received psilocybin in conjunction with psychotherapy experienced significant reductions in depressive symptoms. The study demonstrated that psilocybin could produce rapid and sustained improvements in mood, with many participants reporting lasting positive changes in outlook and behavior [6]. Further studies have shown that psilocybin-assisted psychotherapy can help individuals break free from entrenched thought patterns, leading to long-term improvements in mood and cognition. The therapy typically involves multiple sessions, with the psychedelic experience taking place in a safe, controlled setting and supported by a trained therapist.

MDMA for PTSD

MDMA, a synthetic psychedelic, has shown significant promise

in treating PTSD, particularly in individuals who have not responded to traditional therapies. A Phase 3 clinical trial published in *The Lancet Psychiatry* demonstrated that MDMA-assisted psychotherapy significantly reduced PTSD symptoms and helped individuals process traumatic memories in a therapeutic context. Participants who received MDMA in combination with psychotherapy showed greater reductions in PTSD symptoms compared to those who received a placebo. MDMA is believed to facilitate emotional processing by increasing the release of serotonin, dopamine, and oxytocin, which promote emotional bonding and trust. This makes MDMA particularly well-suited for therapeutic use, as it helps patients engage more deeply with their trauma while feeling safe and supported by the therapist.

LSD for Anxiety and Depression

LSD (lysergic acid diethylamide) has been studied for its effects on anxiety and depression, particularly in individuals with terminal illnesses. In one study published in *The Archives of General Psychiatry*, cancer patients who received LSD-assisted psychotherapy reported significant reductions in anxiety and improved quality of life. The therapy helped patients confront their existential fears and accept their diagnosis, leading to enhanced psychological well-being. LSD, like psilocybin, acts primarily on the serotonin system and is thought to induce similar effects on brain connectivity and emotional processing. While research on LSD is still limited compared to psilocybin and MDMA, the early findings suggest that it holds promise as a treatment for anxiety and existential distress.

Challenges and Future Directions

While the therapeutic potential of psychedelic-assisted psychotherapy is exciting, several challenges remain. One of the primary challenges is the regulatory and legal landscape. In many countries, psychedelics are classified as Schedule I substances, making their clinical use difficult. However, there has been growing support for the reclassification of psychedelics, and some jurisdictions, such as Canada and parts of the United States, have approved limited medical use of psilocybin for patients with treatment-resistant depression. Another challenge is the need for properly trained therapists. Psychedelic-assisted psychotherapy requires a unique skill set, as therapists must navigate altered states of consciousness while maintaining a safe and supportive environment. The integration of these experiences into traditional psychotherapy frameworks also requires careful attention and expertise. Finally, more research is needed to fully understand the long-term effects of psychedelic-assisted psychotherapy. While early studies show promising results, larger, multi-site trials are necessary to confirm the efficacy and safety of these treatments.

Conclusion

Psychedelic-assisted psychotherapy represents an innovative and promising approach to the treatment of mental health disorders, particularly those that are resistant to conventional therapies. By facilitating neuroplasticity, enhancing emotional processing, and promoting new ways of thinking, psychedelics like psilocybin, MDMA, and LSD have the potential to revolutionize the treatment of depression, PTSD, anxiety, and other mental health conditions.

While challenges remain in terms of regulation, therapist training, and long-term research, the growing body of evidence supports

the continued exploration and development of psychedelic-assisted psychotherapy as a valuable tool in mental health care.

References

- 1 Joanna AM, Huczyński KM (2019) Doxycycline, salinomycin, monensin, and ivermectin repositioned as cancer drugs. *Bioorg Med Chem Lett* 29: 1549–1554.
- 2 Miki K, Yagi M, Yoshimoto K, Kang D, Uchiumi T (2017) Induction of mitochondrial dysfunction and oxidative damage by antibiotic drug doxycycline enhances the responsiveness of glioblastoma to chemotherapy. *Med Sci Mon* 23: 4117–4125.
- 3 Shieh J, Huang TF, Hung C, Chou KH (2010) Activation of c-Jun N-terminal kinase is essential for mitochondrial membrane potential change and apoptosis induced by doxycycline in melanoma cells. *Br J Pharmacol* 160: 1171–1184.
- 4 Dong Z, Muhammad NA, Kausar S, Yang J, Li L, et al. (2019) Biological Functions and Molecular Mechanisms of Antibiotic Tigecycline in the Treatment of Cancers. *Int J Mol Sci* 20: 3577.
- 5 Hoffmann M, DeMaio W, Jordan RA, Talaat R, Harper D, et al. (2007) Metabolism, excretion, and pharmacokinetics of [14C]tigecycline, a first-in-class glycycline antibiotic, after intravenous infusion to healthy male subjects. *Drug Metab Dispos* 35: 1543–1553.
- 6 Bahuguna A, Bharatam PV, Rawat DS (2020) An overview of new antitubercular drugs, drug candidates, and their targets. *Med Res Rev* 40: 263–292.